Jukema JW, Zijlstra LE, Bhatt DL, et al. - The PCSK9 inhibitor alirocumab was compared with placebo in 18,924 patients with recent acute coronary syndrome and elevated atherogenic lipoprotein, despite intensive statin therapy, targeting LDL-C level of 25 to 50 mg/dl in ODYSSEY OUTCOMES. Researchers conducted a prespecified analysis investigating the effect of alirocumab on ischemic and hemorrhagic stroke. Randomization of patients to alirocumab or placebo was done 1 to 12 months after acute coronary syndrome. During a median follow-up period of 2.8 years, the occurrence of 263 ischemic and 33 hemorrhagic strokes was reported. Reduced risk of any stroke and ischemic stroke was observed in correlation to receiving alirocumab with no increase in hemorrhagic stroke incidence. This was observed irrespective of baseline LDL-C level and cardiovascular disease history.